MASH prevalence is projected to remain under 5% by 2040, with new treatments like resmetirom now available. Diagnostic challenges and underestimation in claims data affect accurate prevalence ...
Novo Nordisk (NVO) stock gains as its weight loss drug succeeds in Phase 3 trial for the liver disease, MASH hurting Eli ...
With a positive readout for metabolic dysfunction-associated steatohepatitis (MASH) now in the bag, Novo Nordisk is gearing up to pursue yet another indication for its star GLP-1 medicine semaglutide.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback